Clinical study on neuroprotective effect of esketamine on patients with traumatic brain injury

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200057513

Enrollment

Unknown

Registered

2022-03-14

Start date

2022-03-08

Completion date

Unknown

Last updated

2023-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic brain injury

Interventions

Group A:0.15mg/kg/h esketamine

Group B:0.3mg/kg/h esketamine

Group C:continuous infusion of normal saline

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged between 18 and 60 years; 2. Single-site severe craniocerebral trauma assessed by a surgeon requiring surgical intervention; 3. Within 8h after injury; 4. Family members are willing to participate in clinical trials and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergy to the required narcotic drugs; 2. A history of mental illness, drug and alcohol abuse; 3. Dilated pupil, advanced cerebral hernia, brain stem failure; 4. Multiple injuries and severe diseases of heart, liver and kidney function; 5. Second surgery.

Design outcomes

Primary

Measure	Time frame
Inflammatory factor;Markers of brain injury;Glasgow prognosis score;	—

Secondary

Measure	Time frame
Haemodynamics;Sedative analgesic scale;	—

Countries

China

Contacts

Public ContactLiao Xingzhi

Liaoxingzhi@aliyun.com+86 18961881266

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026